Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537991 | PMC |
| http://dx.doi.org/10.1111/ajt.17166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52).
J Clin Med
December 2024
Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, 38206 La Laguna, Spain.
: Post-transplant diabetes mellitus (PTDM) and prediabetes (PreDM) are common after renal transplantation and increase the risk of cardiovascular events and mortality. Compared to immediate-release tacrolimus (IR-Tac), the LCPT formulation, with delayed absorption, offers higher bioavailability and a smoother time-concentration curve, potentially reducing beta-cell stress. : This randomized pilot trial compared de novo immunosuppression with IR-Tac (twice daily) and LCPT (once daily).
View Article and Find Full Text PDFAssessing the Predictive Power of PIRCHE-II Scores for the Development of Donor-Specific Antibodies After Simultaneous Pancreas-Kidney Transplantation.
Transpl Int
January 2025
Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Article Synopsis
- The study investigates the development of donor-specific antibodies (dnDSA) in simultaneous pancreas/kidney transplant recipients (SPKTRs) compared to kidney transplant recipients (KTRs), finding a higher incidence of dnDSA in SPKTRs at one year post-transplant.
- Independent risk factors for dnDSA development identified include preformed DSA and younger donor age, with high PIRCHE-II scores for HLA-DQ correlating significantly with dnDSA.
- However, the research highlights that total PIRCHE-II scores may not reliably predict dnDSA risk, suggesting caution in using this measure for post-transplant assessment.
Key challenges of post-liver transplant weight management.
World J Transplant
December 2024
Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Zagreb 10000, Croatia.
Liver transplantation serves as a life-saving intervention for patients with end-stage liver disease, yet long-term survival remains a challenge. Post-liver transplant obesity seems to have a significant contribution to this challenge and it emerges as a significant risk factor for graft steatosis, metabolic syndrome and de-novo malignancy development. This review synthesizes current literature on prevalence, risk factors and management strategies for post-liver transplant obesity, emphasizing its impact on graft and patient survival.
View Article and Find Full Text PDFPost-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.
Clin Kidney J
December 2024
Department of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
In recent years, advancements in immunosuppressive medications and post-transplant management have led to a significant decrease in acute rejection rates in renal allografts and consequent improvement in short-term graft survival. In contrast, recent data have shown an increased incidence of post-transplant glomerular diseases, which currently represent a leading cause of allograft loss. Although pathogenesis is not fully understood, growing evidence supports the role of inherited and immunological factors and has identified potential pre- and post-transplant predictors.
View Article and Find Full Text PDFHLA class, calcineurin inhibitor levels, and the risk of graft failure in kidney recipients with donor-specific antibodies.
Front Immunol
December 2024
Transplantation Unit, Renal Division, Department of Medicine, University Health Center (CHU) of Quebec, Faculty of Medicine, Laval University, Quebec, QC, Canada.
Introduction: De novo donor-specific HLA antibody (dnDSA) are associated with poor outcomes. Whether this observation applies to both HLA class I and II dnDSA remains unclear.
Methods: We studied 1236 consecutive kidney recipients who had routine anti-HLA antibody surveillance post-transplant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!